Quantcast

Latest Lilly Stories

2014-10-20 16:27:30

INDIANAPOLIS, Oct. 20, 2014 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the fourth quarter of 2014 of $0.49 per share on outstanding common stock. The dividend is payable December 10, 2014 to shareholders of record at the close of business on November 14, 2014. Lilly is a global healthcare leader that unites caring with discovery to make life better for people around the world. We were founded more than a century ago by a...

2014-10-15 12:31:07

BioCrossroads' annual award recognizes Dr. Lechleiter's visionary leadership INDIANAPOLIS, Oct. 15, 2014 /PRNewswire/ -- BioCrossroads today awarded John C. Lechleiter, Ph.D., chairman, president and CEO of Eli Lilly and Company, with the August M. Watanabe Life Sciences Champion of the Year Award, a prestigious honor named in tribute to BioCrossroads' late first Chairman. BioCrossroads presents the Watanabe Award annually to an individual or organization that has made or enabled...

2014-10-13 16:23:18

The Society for Clinical Research Sites recognizes Lilly as the winning sponsor and Quintiles as the winning CRO of the 2014 Eagle Award ELLICOTT CITY, Md., Oct. 13, 2014 /PRNewswire/ -- The Society for Clinical Research Sites (SCRS), the first global trade organization fully dedicated to representing the interests of clinical research sites, announced at the 2014 Site Solutions Summit the winning sponsor and CRO of the 2014 Eagle Award. After thorough analysis of a record number of...

2014-10-06 08:28:45

Fund focuses on achieving human clinical proof-of-concept for early stage drug development projects, following a capital efficient investment approach in collaboration with Lilly MONTREAL and MUNICH, October 6, 2014 /PRNewswire/ -- TVM Capital Life Science, one of the leading life science venture capital firms in Canada, the United States and Europe, today announced the final closing of its latest fund, TVM Life Science Ventures VlI, surpassing its target with more than $200...

2014-10-03 16:24:17

INDIANAPOLIS, Oct. 3, 2014 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will announce its financial results for the third quarter of 2014 on Thursday, October 23, 2014. Lilly will also conduct a conference call on that day with the investment community and media to further detail the company's financial performance. The conference call will be held from 9:00 a.m. to 10:00 a.m. EDT. Investors, media and the general public can access a live webcast of the conference call...

2014-10-02 08:29:46

INDIANAPOLIS, Oct. 2, 2014 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today it will discontinue development of tabalumab­ -- being studied for the treatment of systemic lupus erythematosus (SLE, commonly known as lupus) -- due to insufficient efficacy in two pivotal Phase 3 trials. The decision was not based on safety concerns. ­­­­ In the ILLUMINATE 1 study, tabalumab did not achieve the primary endpoint, at either dose studied, of statistically significant...

2014-09-29 12:30:15

INDIANAPOLIS, Sept. 29, 2014 /PRNewswire/ -- On Oct. 2, some 24,000 Lilly employees spanning nearly 60 countries will participate in the company's seventh Global Day of Service. Building on Lilly's strong heritage of making life better, employees will join together in a single, coordinated effort to improve the communities where they work, live and play. "I'm so proud of this tradition, and of our Lilly people who devote their talent and energy to strengthening the communities around the...

2014-09-18 20:22:43

- Trulicity, a weekly glucagon-like peptide-1 (GLP-1) receptor agonist, is indicated for adults with type 2 diabetes as an adjunct to diet and exercise INDIANAPOLIS, Sept. 18, 2014 /PRNewswire/ -- Trulicity(TM) (dulaglutide), approved today by the U.S. Food and Drug Administration, is the latest Eli Lilly and Company (NYSE: LLY) treatment option for adults with type 2 diabetes. Trulicity is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2...

2014-09-18 08:26:01

-- Phase III RAINBOW Trial Data Published in The Lancet Oncology -- INDIANAPOLIS, Sept. 18, 2014 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that results of the global Phase III trial of ramucirumab (CYRAMZA(TM)) in combination with paclitaxel in patients with advanced gastric (stomach) cancer or gastroesophageal junction (GEJ) adenocarcinoma were published in the online version of The Lancet Oncology. In the trial, known as RAINBOW, the addition of ramucirumab to...

2014-09-16 12:29:51

Company announces a series of digital and employee initiatives honoring women INDIANAPOLIS, Sept. 16, 2014 /PRNewswire/ -- Working Mother magazine has named Eli Lilly and Company as one of its Working Mother 100 Best Companies 20 years in a row. In observance of the honor, Lilly is planning a series of digital and employee initiatives. Working Mother annually honors companies for outstanding leadership in establishing policies, programs and a corporate culture that supports working mothers,...


Word of the Day
abrosia
  • Wasting away as a result of abstinence from food.
The word 'abrosia' comes from a Greek roots meaning 'not' and 'eating'.